Showing results (31-40 of 81) with videos related to

Sort By:
Pageof 9
Cancer|January 28, 2003
Third North American Symposium on Skeletal Complications of Malignancy: summary of the scientific sessionsSuresh Mohla, Katherine N Weilbacher, Michael L Cher, et al.
Genes & Development|July 18, 2009
ADAMTS1 and MMP1 proteolytically engage EGF-like ligands in an osteolytic signaling cascade for bone metastasisXin Lu, Qiongqing Wang, Guohong Hu, et al.
Journal of Bone Reports & Recommendations|October 1, 2016
Adjuvant Aromatase Inhibitors in Early Breast Cancer May Not Increase the Risk of FallsPalak Choksi, Margaret E Williams, Kelley M Kidwel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2002
Assessment of molecular markers of clinical sensitivity to single-agent taxane therapy for metastatic breast cancerCatherine Van Poznak, Lee Tan, Katherine S Panageas, et al.
Neuro-Oncology|January 29, 2014
Phase II trial of patupilone in patients with brain metastases from breast cancerDavid M Peereboom, Conleth Murphy, Manmeet S Ahluwalia, et al.
Cancer|June 22, 2011
Pilot study of duloxetine for treatment of aromatase inhibitor-associated musculoskeletal symptomsN Lynn Henry, Mousumi Banerjee, Max Wicha, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 13, 2010
Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trialCatherine Van Poznak, Rosemary A Hannon, John R Mackey, et al.
Clinical Breast Cancer|February 6, 2010
Intravenous bisphosphonate therapy does not acutely alter nuclear bone scan resultsPatrick G Morris, Catherine Van Poznak, Shanu Modi, et al.
Breast Cancer Research and Treatment|May 13, 2019
De-escalation of bone-modifying agents in patients with bone metastases from breast cancer: a systematic review and meta-analysisArif Ali Awan, Brian Hutton, John Hilton, et al.
Pageof 9